WallStreetZen

NYSE: ABT
Abbott Laboratories Stock Forecast, Predictions & Price Target

Analyst price target for ABT

Based on 12 analysts offering 12 month price targets for Abbott Laboratories.
Min Forecast
$107.00-3.86%
Avg Forecast
$117.92+5.94%
Max Forecast
$130.00+16.8%

Should I buy or sell ABT stock?

Strong Buy
Strong Buy
11 analysts 78.57%
Buy
1 analysts 7.14%
Hold
2 analysts 14.29%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is ABT forecast to generate an efficient return?
Company
31.38%
Industry
28.91%
Market
62.25%
ABT's Return on Equity is forecast to be high in 4 years (31.38%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is ABT forecast to generate an efficient return on assets?
Company
14.36%
Industry
14.48%
Market
19.66%
ABT is forecast to generate lower Return on Assets (14.36%) than the US Medical Devices industry average (14.48%)
Forecast

ABT earnings per share forecast

What is ABT's earnings per share in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$4.38+130.68%
Avg 2 year Forecast
$4.53+138.35%
Avg 3 year Forecast
$5.19+173.16%
ABT's earnings are forecast to grow at an exceptional rate of 37.78% per year
Forecast

ABT revenue forecast

What is ABT's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$38.6B+19.64%
Avg 2 year Forecast
$39.8B+23.39%
Avg 3 year Forecast
$43.0B+33.45%
ABT's revenue is forecast to grow at a rate of 9.43% per year, which is not exceptional
Forecast

ABT earnings growth forecast

How is ABT forecast to perform vs Medical Devices companies and vs the US market?
Company
37.78%
Industry
25.02%
Market
20.47%
ABT's earnings are forecast to grow faster (37.78% per year) than the US Medical Devices industry average (25.02%)
Forecast
ABT's earnings are forecast to grow faster (37.78% per year) than the US market average (20.47%)
Forecast
ABT's earnings are forecast to grow faster (37.78% per year) than the risk-free savings rate (1.1%)
Forecast

ABT revenue growth forecast

How is ABT forecast to perform vs Medical Devices companies and vs the US market?
Company
9.43%
Industry
10.41%
Market
14.48%
ABT's revenues are forecast to grow slower (9.43% per year) than the US Medical Devices industry average (10.41%)
Forecast
ABT's revenues are forecast to grow slower (9.43% per year) than the US market average (14.48%)
Forecast

Abbott Laboratories Stock Forecast FAQ

Is Abbott Laboratories Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 14 Wall Street analysts covering (NYSE: ABT) stock is to Strong Buy ABT stock.

Out of 14 analysts, 11 (78.57%) are recommending ABT as a Strong Buy, 1 (7.14%) are recommending ABT as a Buy, 2 (14.29%) are recommending ABT as a Hold, 0 (0%) are recommending ABT as a Sell, and 0 (0%) are recommending ABT as a Strong Sell.

What is ABT's Price Target?

According to 12 Wall Street analysts that have issued a 1 year ABT price target, the average ABT price target is $117.92, with the highest ABT stock price forecast at $130.00 and the lowest ABT stock price forecast at $107.00.

On average, Wall Street analysts predict that Abbott Laboratories's share price could reach $117.92 by Jan 8, 2022. The average Abbott Laboratories stock price prediction forecasts a potential upside of 5.94% from the current ABT share price of $111.30.

What is ABT's earnings growth forecast for 2021-2023?

(NYSE: ABT) Abbott Laboratories's forecast annual earnings growth rate of 37.78% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 25.02%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.47%.

Abbott Laboratories's earnings in 2020 is $3,382,000,000.On average, 10 Wall Street analysts forecast ABT's earnings for 2021 to be $7,760,232,986, with the lowest ABT earnings forecast at $7,613,278,996, and the highest ABT earnings forecast at $7,896,563,796. On average, 7 Wall Street analysts forecast ABT's earnings for 2022 to be $8,018,022,153, with the lowest ABT earnings forecast at $7,436,225,996, and the highest ABT earnings forecast at $8,286,080,395.

In 2023, ABT is forecast to generate $9,189,050,695 in earnings, with the lowest earnings forecast at $9,082,818,895 and the highest earnings forecast at $9,295,282,495.

What is ABT's revenue growth forecast for 2021-2023?

(NYSE: ABT) Abbott Laboratories's forecast annual revenue growth rate of 9.43% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 10.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.

Abbott Laboratories's revenue in 2020 is $32,221,000,000.On average, 7 Wall Street analysts forecast ABT's revenue for 2021 to be $68,254,652,067,160, with the lowest ABT revenue forecast at $67,633,502,339,200, and the highest ABT revenue forecast at $68,902,600,537,184. On average, 6 Wall Street analysts forecast ABT's revenue for 2022 to be $70,390,284,827,783, with the lowest ABT revenue forecast at $67,529,784,691,859, and the highest ABT revenue forecast at $72,809,505,148,877.

In 2023, ABT is forecast to generate $76,131,019,427,001 in revenue, with the lowest revenue forecast at $76,058,427,697,042 and the highest revenue forecast at $76,203,611,156,960.

What is ABT's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: ABT) Abbott Laboratories's current Earnings Per Share (EPS) is $1.90. On average, analysts forecast that ABT's EPS will be $4.38 for 2021, with the lowest EPS forecast at $4.30, and the highest EPS forecast at $4.46. On average, analysts forecast that ABT's EPS will be $4.53 for 2022, with the lowest EPS forecast at $4.20, and the highest EPS forecast at $4.68. In 2023, ABT's EPS is forecast to hit $5.19 (min: $5.13, max: $5.25).

What is ABT's forecast return on equity (ROE) for 2021-2024?

(NYSE: ABT) forecast ROE is 31.38%, which is considered strong.

What is ABT's forecast return on assets (ROA) for 2021-2024?

(NYSE: ABT) forecast ROA is 14.36%, which is lower than the forecast US Medical Devices industry average of 14.48%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics